0001193125-24-156049.txt : 20240606 0001193125-24-156049.hdr.sgml : 20240606 20240606160630 ACCESSION NUMBER: 0001193125-24-156049 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240605 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20240606 DATE AS OF CHANGE: 20240606 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Stoke Therapeutics, Inc. CENTRAL INDEX KEY: 0001623526 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 471144582 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38938 FILM NUMBER: 241025048 BUSINESS ADDRESS: STREET 1: 45 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: 781-430-8200 MAIL ADDRESS: STREET 1: 45 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 FORMER COMPANY: FORMER CONFORMED NAME: ASOthera Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20141028 8-K 1 d795894d8k.htm 8-K 8-K
false 0001623526 0001623526 2024-06-05 2024-06-05

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 5, 2024

 

 

Stoke Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-38938   47-1144582
(State or Other Jurisdiction
of Incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

45 Wiggins Ave  
Bedford, Massachusetts   01730
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (781) 430-8200

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, $0.0001 par value per share   STOK   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.07

Submission of Matters to a Vote of Security Holders.

On June 5, 2024, Stoke Therapeutics, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders, and the following proposals were adopted:

 

1.

Election of three Class II directors, Jennifer C. Burstein, Arthur A. Levin, Ph.D. and Ian F. Smith, each to serve a three-year term, which will expire upon the earlier of the 2027 Annual Meeting of Stockholders or until such time as their respective successors have been duly elected and qualified:

 

Nominees

  

Shares For

  

Shares Withheld

  

Broker Non-Votes

Jennifer C. Burstein

   32,396,633   1,970,217   5,561,508

Arthur A. Levin, Ph.D.

   25,556,568   8,810,282   5,561,508

Ian F. Smith

   33,961,032   405,818   5,561,508

 

2.

Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024:

 

Shares For

  

Shares Against

  

Shares Withheld/Abstaining

39,911,634

   6,826   9,898

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 6, 2024

 

STOKE THERAPEUTICS, INC.
By:  

/s/ Thomas Leggett

  Thomas Leggett
  Chief Financial Officer
 EX-101.SCH 2 stok-20240605.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 stok-20240605_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 stok-20240605_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
Jun. 05, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001623526
Document Type 8-K
Document Period End Date Jun. 05, 2024
Entity Registrant Name Stoke Therapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-38938
Entity Tax Identification Number 47-1144582
Entity Address, Address Line One 45 Wiggins Ave
Entity Address, City or Town Bedford
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01730
City Area Code (781)
Local Phone Number 430-8200
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol STOK
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.stoketherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d795894d8k.htm stok-20240605.xsd stok-20240605_lab.xml stok-20240605_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d795894d8k.htm": { "nsprefix": "stok", "nsuri": "http://www.stoketherapeutics.com/20240605", "dts": { "inline": { "local": [ "d795894d8k.htm" ] }, "schema": { "local": [ "stok-20240605.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "stok-20240605_lab.xml" ] }, "presentationLink": { "local": [ "stok-20240605_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.stoketherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-06-05_to_2024-06-05", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d795894d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-06-05_to_2024-06-05", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d795894d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.stoketherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.stoketherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.stoketherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.stoketherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.stoketherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.stoketherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.stoketherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.stoketherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.stoketherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.stoketherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.stoketherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.stoketherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.stoketherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.stoketherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.stoketherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.stoketherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.stoketherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.stoketherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.stoketherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.stoketherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.stoketherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.stoketherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.stoketherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001193125-24-156049-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-156049-xbrl.zip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end XML 16 d795894d8k_htm.xml IDEA: XBRL DOCUMENT 0001623526 2024-06-05 2024-06-05 false 0001623526 8-K 2024-06-05 Stoke Therapeutics, Inc. DE 001-38938 47-1144582 45 Wiggins Ave Bedford MA 01730 (781) 430-8200 false false false false Common Stock, $0.0001 par value per share STOK NASDAQ true false